News and Press Releases
Samsung Bioepis Reaches Settlement Agreement for Eylea (Aflibercept) Biosimilar in Europe and the Rest of the World
30 January 2026 -- Incheon, Korea -- Samsung Bioepis Co., Ltd. has signed a settlement and license agreement with Regeneron and Bayer concerning the commercialization of SB15, a biosimilar to...
Category: Drug Discovery, Other, Pharmaceutical
Posted: January 30, 2026
Intellia Therapeutics Provides Update on MAGNITUDE Clinical Trials of Nexiguran Ziclumeran (nex-z)
27 October 2025 -- Massachusetts, US -- Intellia Therapeutics, Inc, a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced that the company has temporarily...
Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: October 27, 2025
40 Erie Street, Suite 130, Cambridge, MA 02139
CRISPR Therapeutics Presents New Preclinical Data for CTX460 Demonstrating In Vivo Gene Correction of Alpha-1 Antitrypsin Deficiency (AATD) Utilizing Novel SyNTase Editing Platform
Preclinical data presented at the European Society of Gene and Cell Therapy (ESGCT) highlight a potential best-in-class profile The AATD program, CTX460, is the first investigational candidate to emerge from the SyNTase editing platform...
Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: October 10, 2025
Editas Medicine Reports In Vivo Proof-of-Concept Data for EDIT-401 at the European Society of Gene and Cell Therapy (ESGCT) 32nd Annual Congress
Preclinical data demonstrates proof-of-concept for EDIT-401 with ≥90% mean LDL-C reduction in non-human primates and mouse models 9 October 2025 -- Massachusetts, US -- Editas Medicine, Inc, a pioneering gene editing company,...
Category: Biotechnology, Drug Discovery, Other, Pharmaceutical
Posted: October 9, 2025
Formycon secures U.S. License Date for proposed Aflibercept Biosimilar FYB203 following settlement and license agreement with Regeneron
Formycon and its partners entered into a settlement and license agreement with Regeneron for FYB203/AHZANTIVE (Aflibercept-mrbb) Pending litigation at the U.S. District Court for the Northern District of West Virginia...
Category: Logistics, Other, Pharmaceutical
Posted: October 2, 2025
Biocon Biologics Secures U.S. Market Entry Date for Bosaya and Aukelso, Denosumab Biosimilars
1 October 2025 -- Bengaluru, India and New Jersey, US -- Biocon Biologics Ltd, a fully integrated global biosimilars company and subsidiary of Biocon Ltd, today announced a settlement and...
Category: Logistics, Other, Pharmaceutical
Posted: October 1, 2025
Biocon House, Semicon Park Electronics City, Phase – II, Hosur Road Bengaluru 560100, Karnataka, India
Ocugen, Inc. and Kwangdong Pharmaceutical Co., Ltd. Complete License Agreement of OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in Korea
Upfront fees and near-term development milestone payments totaling up to $7.5 million Potential sales milestones of $180 million or more in first 10 years of commercialization Royalties equaling 25% of...
Category: Biotechnology, Drug Discovery, Other, Pharmaceutical
Posted: September 15, 2025
Two Weeks to Go – London Biotechnology Show 2025 Gears Up to Spotlight Industry Pioneers, Disruptive Tech, Emerging Innovators
2 June 2025 -- London, UK -- In just two weeks, the second edition of the London Biotechnology Show (LBS) returns to ExCeL London on 18–19 June, bringing together one...
Category: BioManufacturing, Biotechnology, Drug Discovery, Other, Pharmaceutical
Posted: June 2, 2025
Breakthrough Gene Editing Technique Offers Hope for Stargardt Disease Patients
8 January 2025 -- Basel, Switzerland -- Researchers have developed a highly efficient gene editing therapy that could potentially treat Stargardt disease, the most common form of inherited macular degeneration....
Category: Biotechnology, Clinical Trials, Other, Pharmaceutical
Posted: January 8, 2025
Mittlere Strasse 91, CH-4031 Basel, Switzerland
ERS Genomics and Université de Montréal sign CRISPR/Cas9 license agreement
License agreement provides Université de Montréal access to CRISPR gene editing technology for use across its platform services 1 October 2024 -- Dublin, Ireland, and Montreal, Canada -- ERS Genomics...
Category: Biotechnology, Clinical Trials, Drug Discovery
Posted: October 1, 2024
ERS Genomics and Medicines Discovery Catapult sign CRISPR/Cas9 license agreement
Partnership provides Medicines Discovery Catapult access to CRISPR gene editing technology across a broad range of drug discovery applications 04 September 2024 – Dublin, Ireland, and Cheshire, UK – ERS...
Category: BioManufacturing
Posted: September 9, 2024
ERS Genomics and IRBM sign CRISPR/Cas9 license agreement
License agreement provides IRBM access to CRISPR gene editing technology to be applied across its drug discovery services offering 20 May 2024 -- Dublin, Ireland, and Rome, Italy -- ERS...
Category: Biotechnology, Drug Discovery, Pharmaceutical
Posted: May 20, 2024
ERS Genomics appoints John E Milad as Chief Executive Officer
13 May 2024 -- Dublin, Ireland -- ERS Genomics, the CRISPR licensing company, today announced the appointment of John E Milad as CEO, with immediate effect. John brings over 25...
Category: Drug Delivery, Drug Discovery
Posted: May 13, 2024
Ricoh and ERS Genomics enter into CRISPR/Cas9 license agreement
CRISPR/Cas9 genome editing technology contributes to the expansion of the creation of novel disease model 13 March 2024 -- Tokyo, Japan, and Dublin, Ireland -- Ricoh Company today announced a...
Category: Biotechnology
Posted: March 13, 2024
